Total Payments
$465.12
2024 Payments
$45.11
Companies
14
Transactions
30
Medicare Patients
17,106
Medicare Billing
$7.8M
Payment Breakdown by Category
Food & Beverage$385.89 (83.0%)
Education$79.23 (17.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $385.89 | 28 | 83.0% |
| Education | $79.23 | 2 | 17.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $109.67 | 9 | $0 (2018) |
| GlaxoSmithKline, LLC. | $58.39 | 3 | $0 (2018) |
| Amgen Inc. | $57.31 | 3 | $0 (2018) |
| Ferring Pharmaceuticals Inc. | $32.33 | 2 | $0 (2018) |
| Janssen Biotech, Inc. | $30.49 | 2 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $26.75 | 1 | $0 (2023) |
| UCB, Inc. | $26.71 | 1 | $0 (2019) |
| Organon Llc | $22.43 | 3 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $19.88 | 1 | $0 (2018) |
| PFIZER INC. | $19.00 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $45.11 | 4 | Celgene Corporation ($15.60) |
| 2023 | $33.68 | 2 | AstraZeneca Pharmaceuticals LP ($26.75) |
| 2021 | $19.00 | 1 | PFIZER INC. ($19.00) |
| 2019 | $26.71 | 1 | UCB, Inc. ($26.71) |
| 2018 | $232.48 | 16 | Genentech USA, Inc. ($109.67) |
| 2017 | $108.14 | 6 | Amgen Inc. ($39.43) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2024 | Organon Llc | RENFLEXIS (Drug), HADLIMA | Food and Beverage | In-kind items and services | $6.97 | General |
| Category: INFLIXIMAB | ||||||
| 08/21/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: IMMUNOLOGY | ||||||
| 05/21/2024 | Celgene Corporation | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $15.60 | General |
| Category: Immunology | ||||||
| 04/09/2024 | Organon Llc | RENFLEXIS (Drug), HADLIMA | Food and Beverage | In-kind items and services | $8.53 | General |
| Category: INFLIXIMAB | ||||||
| 08/02/2023 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $26.75 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 05/03/2023 | Organon LLC | RENFLEXIS (Drug) | Food and Beverage | In-kind items and services | $6.93 | General |
| Category: INFLIXIMAB | ||||||
| 07/21/2021 | PFIZER INC. | XELJANZ (Drug), INFLECTRA | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/12/2019 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $26.71 | General |
| Category: Immunology | ||||||
| 12/19/2018 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Immunology | ||||||
| 12/12/2018 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: RESPIRATORY | ||||||
| 09/05/2018 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $2.74 | General |
| Category: BioOncology/Immunology | ||||||
| 09/05/2018 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $0.77 | General |
| Category: BioOncology/Immunology | ||||||
| 08/29/2018 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: Inflammation | ||||||
| 08/02/2018 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $3.93 | General |
| Category: BioOncology/Immunology | ||||||
| 07/31/2018 | Regeneron Healthcare Solutions, Inc. | KEVZARA SARILUMAB INJECTION (Biological) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 07/11/2018 | Ferring Pharmaceuticals Inc. | EUFLEXXA (Device) | Education | In-kind items and services | $18.23 | General |
| Category: ORTHOPEDICS | ||||||
| 07/10/2018 | Genentech USA, Inc. | Rituxan (Biological), Actemra | Education | In-kind items and services | $61.00 | General |
| Category: BioOncology/Immunology | ||||||
| 07/09/2018 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: BioOncology/Immunology | ||||||
| 06/27/2018 | Genentech USA, Inc. | Rituxan (Biological), Actemra | Food and Beverage | In-kind items and services | $5.39 | General |
| Category: BioOncology/Immunology | ||||||
| 03/28/2018 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: IMMUNOLOGY | ||||||
| 03/22/2018 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $3.67 | General |
| Category: BioOncology/Immunology | ||||||
| 02/28/2018 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: BioOncology/Immunology | ||||||
| 02/07/2018 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $3.47 | General |
| Category: BioOncology/Immunology | ||||||
| 01/11/2018 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), STELARA | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: Immunology | ||||||
| 11/29/2017 | Ferring Pharmaceuticals Inc. | EUFLEXXA (Device) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: ORTHOPEDICS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 47 | 4,373 | 156,012 | $5.3M | $2.3M |
| 2022 | 44 | 4,790 | 127,713 | $5.5M | $2.5M |
| 2021 | 48 | 4,337 | 95,180 | $4.2M | $1.8M |
| 2020 | 39 | 3,606 | 38,750 | $2.9M | $1.2M |
Total Patients
17,106
Total Services
417,655
Medicare Billing
$7.8M
Procedure Codes
178
All Medicare Procedures & Services
178 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 35 | 17,575 | $1.2M | $583,779 | 50.3% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 58 | 47,800 | $1.2M | $500,326 | 41.9% |
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 24 | 6,788 | $767,044 | $395,342 | 51.5% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 11 | 32,880 | $295,920 | $153,089 | 51.7% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 22 | 5,230 | $287,650 | $136,005 | 47.3% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 13 | 30,800 | $246,400 | $120,558 | 48.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 563 | 1,135 | $460,810 | $96,461 | 20.9% |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 2023 | 24 | 2,490 | $191,730 | $77,996 | 40.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 146 | 628 | $264,368 | $63,251 | 23.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 29 | 2,280 | $72,960 | $41,612 | 57.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 113 | 113 | $59,551 | $13,119 | 22.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 86 | 208 | $48,880 | $10,240 | 20.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 35 | 180 | $36,858 | $10,220 | 27.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 437 | 931 | $16,758 | $9,506 | 56.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 428 | 921 | $11,973 | $6,913 | 57.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 56 | 325 | $30,773 | $6,874 | 22.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 389 | 665 | $9,975 | $5,528 | 55.4% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 51 | 87 | $26,520 | $4,978 | 18.8% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 432 | 928 | $8,352 | $4,651 | 55.7% |
| 85651 | Red blood cell sedimentation rate, to detect inflammation, non-automated | Office | 2023 | 430 | 893 | $7,114 | $3,680 | 51.7% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 47 | 47 | $4,360 | $3,381 | 77.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 49 | 274 | $13,974 | $3,175 | 22.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 110 | 154 | $6,930 | $1,611 | 23.2% |
| 86235 | Measurement of antibody for assessment of autoimmune disorder, any method | Office | 2023 | 15 | 85 | $2,607 | $1,494 | 57.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 49 | 49 | $3,920 | $1,481 | 37.8% |
About Dr. Dominik Sokalski, M.D
Dr. Dominik Sokalski, M.D is a Rheumatology healthcare provider based in Medford, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/25/2007. The National Provider Identifier (NPI) number assigned to this provider is 1104016278.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dominik Sokalski, M.D has received a total of $465.12 in payments from pharmaceutical and medical device companies, with $45.11 received in 2024. These payments were reported across 30 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($385.89).
As a Medicare-enrolled provider, Sokalski has provided services to 17,106 Medicare beneficiaries, totaling 417,655 services with total Medicare billing of $7.8M. Data is available for 4 years (2020–2023), covering 178 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Other Specialties Rheumatology
- Location Medford, OR
- Active Since 07/25/2007
- Last Updated 02/11/2019
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1104016278
Products in Payments
- Rituxan (Biological) $109.67
- Enbrel (Biological) $57.31
- BENLYSTA (Biological) $37.18
- EUFLEXXA (Device) $32.33
- SIMPONI ARIA (Biological) $30.49
- SAPHNELO (Biological) $26.75
- Cimzia (Drug) $26.71
- RENFLEXIS (Drug) $22.43
- NUCALA (Biological) $21.21
- COSENTYX (Biological) $19.88
- XELJANZ (Drug) $19.00
- BOTOX CHRONIC MIGRAINE (Drug) $17.43
- ORENCIA (Biological) $15.60
- KEVZARA SARILUMAB INJECTION (Biological) $15.12
- RINVOQ (Biological) $14.01
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.